Lilly and Novo bosses agree: There is plenty of room for other obesity players
Eli Lilly CEO David Ricks envisions a growing market for obesity drugs with room for more players than just Novo Nordisk and Eli Lilly, reports Danish business daily Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.